{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:37Z","timestamp":1792788157218,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The RA Registry was sponsored by CorEvitas, LLC and this analysis was funded by Sanofi."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the effects of tumor necrosis factor inhibitors (TNFi), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on hemoglobin (Hb) and C-reactive protein (CRP) levels in adults enrolled in CorEvitas (formerly Corrona), a large US rheumatoid arthritis (RA) registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who initiated TNFi, IL-6Ri, or JAKi treatment during or after January 2010, had Hb and CRP measurements at baseline and 6-month follow-up (\u00b1 3 months) and had continued therapy at least until that follow-up, through March 2020, were included in the analysis. Changes in Hb and CRP were assessed at month 6. Abnormal Hb was defined as &lt; 12 g\/dL (women) or &lt; 13 g\/dL (men); abnormal CRP was \u2265 0.8 mg\/dL. Differences in Hb and CRP levels were evaluated using multivariable regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 2772 patients (TNFi, 65%; IL-6Ri, 17%; JAKi, 17%) evaluated, 1044 (38%) had abnormal Hb or CRP at initiation; an additional 252 (9%) had both abnormal Hb and CRP. At month 6, the IL-6Ri group had a greater Hb increase than the TNFi (mean difference in effect on Hb: 0.28 g\/dL; 95% CI 0.19\u20130.38) and JAKi (mean difference in effect on Hb: 0.47 g\/dL; 95% CI 0.35\u20130.58) groups, regardless of baseline Hb status (both\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). The CRP decrease at month 6 was greater with IL-6Ri compared with TNFi and JAKi, regardless of baseline CRP status (both\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These real-world results align with the mechanism of IL-6R inhibition and may inform treatment decisions for patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-022-02955-y","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:03:57Z","timestamp":1671584637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry"],"prefix":"10.1186","volume":"24","author":[{"given":"Anthony S.","family":"Padula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-027X","authenticated-orcid":false,"given":"Dimitrios A.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor S.","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelechi","family":"Emeanuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"1","key":"2955_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"2955_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr","year":"1990","unstructured":"Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277\u201389.","journal-title":"N Engl J Med"},{"issue":"2","key":"2955_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/clim.1999.4736","volume":"92","author":"PV Voulgari","year":"1999","unstructured":"Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol. 1999;92(2):153\u201360.","journal-title":"Clin Immunol"},{"issue":"6","key":"2955_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"2955_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","volume":"102","author":"T Ganz","year":"2003","unstructured":"Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783\u20138.","journal-title":"Blood."},{"issue":"10","key":"2955_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011\u201323.","journal-title":"N Engl J Med"},{"issue":"11","key":"2955_CR7","first-page":"2430","volume":"28","author":"JP Kaltwasser","year":"2001","unstructured":"Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001;28(11):2430\u20136.","journal-title":"J Rheumatol"},{"issue":"11","key":"2955_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","volume":"57","author":"EHS Choy","year":"2018","unstructured":"Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885\u201395.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2955_CR9","first-page":"2177","volume":"34","author":"C Han","year":"2007","unstructured":"Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol. 2007;34(11):2177\u201382.","journal-title":"J Rheumatol"},{"issue":"7","key":"2955_CR10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","volume":"101","author":"E Nemeth","year":"2003","unstructured":"Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461\u20133.","journal-title":"Blood."},{"issue":"Suppl 7A","key":"2955_CR11","doi-asserted-by":"publisher","first-page":"50S","DOI":"10.1016\/j.amjmed.2003.12.012","volume":"116","author":"A Wilson","year":"2004","unstructured":"Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):50S\u20137S.","journal-title":"Am J Med"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3389\/fphys.2019.01294","volume":"10","author":"A Pagani","year":"2019","unstructured":"Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and anemia: a tight relationship. Front Physiol. 2019;10:1294.","journal-title":"Front Physiol"},{"issue":"6","key":"2955_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2169\/internalmedicine.48.1578","volume":"48","author":"MD Demirag","year":"2009","unstructured":"Demirag MD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med. 2009;48(6):421\u20136.","journal-title":"Intern Med"},{"issue":"3","key":"2955_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3346\/jkms.2010.25.3.348","volume":"25","author":"HR Kim","year":"2010","unstructured":"Kim HR, Kim KW, Yoon SY, Kim SH, Lee SH. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci. 2010;25(3):348\u201352.","journal-title":"J Korean Med Sci"},{"issue":"5","key":"2955_CR15","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar4323","volume":"15","author":"SN Song","year":"2013","unstructured":"Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):R141.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2955_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/ard.52.3.232","volume":"52","author":"R Madhok","year":"1993","unstructured":"Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2955_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702\u201310.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2955_CR18","first-page":"425","volume":"21","author":"MA van Leeuwen","year":"1994","unstructured":"van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol. 1994;21(3):425\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"2955_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","volume":"51","author":"JE Pope","year":"2021","unstructured":"Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219\u201329.","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 10","key":"2955_CR20","first-page":"Abstract 1528","volume":"70","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Hagino O, Dong Q, Stanislav M, Gomez-Centeno A, Selmi C, et al. Unique changes in hemoglobin with sarilumab versus adalimumab are independent of better disease control in patients with rheumatoid arthritis (RA). Arthritis. Rheumatol. 2018;70(suppl 10):Abstract 1528.","journal-title":"Rheumatol."},{"issue":"suppl 10","key":"2955_CR21","first-page":"Abstract 2761","volume":"67","author":"M Dougados","year":"2015","unstructured":"Dougados M, Choy EH, Kameda H, van Adelsberg J, Fay J, Fiore S, et al. IL-6R blockade with sarilumab plus methotrexate results in changes in clinical and laboratory parameters associated with chronic inflammation in patients with moderate-to-severe RA in a phase 3 study. Arthritis Rheum. 2015;67(suppl 10):Abstract 2761.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2955_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2008.08.002","volume":"39","author":"MK Doyle","year":"2009","unstructured":"Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum. 2009;39(2):123\u201331.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2955_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098202","volume":"9","author":"M Hashimoto","year":"2014","unstructured":"Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, et al. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PLoS One. 2014;9(5):e98202.","journal-title":"PLoS One"},{"issue":"1","key":"2955_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017;56(1):46\u201357.","journal-title":"Rheumatology (Oxford)"},{"key":"2955_CR25","unstructured":"CorEvitas. Rheumatoid arthritis registry. Available from https:\/\/www.corrona.org\/registry\/rheumatoid-arthritis. Accessed 19 Nov 2020."},{"key":"2955_CR26","first-page":"iv37","volume":"64 Suppl 4","author":"J Kremer","year":"2005","unstructured":"Kremer J. The CORRONA database. Ann Rheum Dis. 2005;64 Suppl 4:iv37\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2955_CR27","unstructured":"WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO\/NMH\/NHD\/MNM\/11.1). Available from http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf. Accessed 16 Oct 2021."},{"issue":"5","key":"2955_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jhm.650","volume":"5","author":"A Languasco","year":"2010","unstructured":"Languasco A, Cazap N, Marciano S, Huber M, Novillo A, Poletta F, et al. Hemoglobin concentration variations over time in general medical inpatients. J Hosp Med. 2010;5(5):283\u20138.","journal-title":"J Hosp Med"},{"issue":"10","key":"2955_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"2955_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2955_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"2955_CR32","doi-asserted-by":"publisher","first-page":"Poster SAT0100","DOI":"10.1136\/annrheumdis-2020-eular.2008","volume":"79","author":"G Burmester","year":"2020","unstructured":"Burmester G, Morello J, Hagino O, Praestgaard A, Fiore S, Genovese M. Association between low hemoglobin and radiographic progression over 52 weeks in patients with rheumatoid arthritis: results from a phase 3 trial of sarilumab. Ann Rheum Dis. 2020;79(Suppl 1):Poster SAT0100.","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"2955_CR33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"2955_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2955_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/01.CIR.0000053731.05365.5A","volume":"107","author":"ET Yeh","year":"2003","unstructured":"Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107(3):370\u20131.","journal-title":"Circulation."},{"issue":"8","key":"2955_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160225","volume":"11","author":"M Kochi","year":"2016","unstructured":"Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis. PLoS One. 2016;11(8):e0160225.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"2955_CR37","doi-asserted-by":"publisher","first-page":"Poster FRI0108","DOI":"10.1136\/annrheumdis-2020-eular.2181","volume":"79","author":"J Tesser","year":"2020","unstructured":"Tesser J, Wright G, Strand V, Kaine J, Maslova K, St John G, et al. Association between changes in C-reactive protein at Week 12 and patient-reported outcomes at Week 24 with sarilumab therapy across three pivotal phase 3 studies. Ann Rheum Dis. 2020;79(Suppl 1):Poster FRI0108.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02955-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:08:07Z","timestamp":1671584887000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02955-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02955-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review were obtained through a central IRB (New England Independent Review Board, NEIRB No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs, and documentation of approval was submitted to the sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ASP has nothing to disclose. DAP is an employee of CorEvitas, LLC and may own company stock; he is also a consultant for Novartis, Regeneron, and Roche. SF and KF are employees of Sanofi and may hold shares and\/or stock options in the company. TSB is an employee of CorEvitas, LLC. KE was an employee of CorEvitas, LLC during the development of this study. JMK has an equity interest in CorEvitas, LLC and consults for them.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}